Loading
A phase 2 trial of Eltrombopag and Lenalidomide in Leukaemia, run by Albert Einstein College of Medicine, completed.
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia is a phase 2 interventional study registered as NCT01772420 by Albert Einstein College of Medicine, with 52 participants recorded, started 2012-10 and reaching its primary completion in 2020-07-09. Interventions recorded: Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide. Conditions recorded: Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia.
Linked to the drug Eltrombopag because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
52 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2023-07-27), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Patients Demonstrating Overall Hematologic Improvement (HI)primary | Arm A (Platelets > 50,000 k/uL) LEN Initiation | 16 | 6 participants | - | - | link |
| Arm B (Platelets < 50,000 k/uL) ELT Initiation With Potential LEN Combination | 15 | 5 participants | ||||
| Arm C (Platelets < 50,000 k/uL) ELT Monotherapy | 21 | 7 participants |
Shares Eltrombopag, Leukaemia (all types) and the tag pipeline.
Shares Eltrombopag and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.